Published in Hum Immunol on December 28, 2011
Characterization of CD4+ T cell subsets in allergy. Curr Opin Immunol (2012) 0.85
Identification and validation of shrimp-tropomyosin specific CD4 T cell epitopes. Hum Immunol (2013) 0.84
Arginine kinase Pen m 2 as an important shrimp allergen recognized by TH2 cells. J Allergy Clin Immunol (2014) 0.80
Effect of thermal processing on T cell reactivity of shellfish allergens - Discordance with IgE reactivity. PLoS One (2017) 0.75
Monitoring lymphocyte proliferation in vitro and in vivo with the intracellular fluorescent dye carboxyfluorescein diacetate succinimidyl ester. Nat Protoc (2007) 3.45
Reconstitution of troponin activity from three protein components. J Biol Chem (1971) 3.13
Role of interleukin 10 in specific immunotherapy. J Clin Invest (1998) 2.57
Effect of T-cell peptides derived from Fel d 1 on allergic reactions and cytokine production in patients sensitive to cats: a randomised controlled trial. Lancet (2002) 2.38
Induction of IL-10+CD4+CD25+ T cells by grass pollen immunotherapy. J Allergy Clin Immunol (2003) 1.94
Prevalence of seafood allergy in the United States determined by a random telephone survey. J Allergy Clin Immunol (2004) 1.90
Efficacy and safety of sublingual immunotherapy with grass allergen tablets for seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol (2006) 1.87
Peptide immunotherapy in allergic asthma generates IL-10-dependent immunological tolerance associated with linked epitope suppression. J Exp Med (2009) 1.73
Sublingual immunotherapy induces IL-10-producing T regulatory cells, allergen-specific T-cell tolerance, and immune deviation. J Allergy Clin Immunol (2007) 1.64
Identification of an immunodominant region of Fel d 1 and characterization of constituent epitopes. Clin Exp Allergy (2008) 1.59
Successful immunotherapy with T-cell epitope peptides of bee venom phospholipase A2 induces specific T-cell anergy in patients allergic to bee venom. J Allergy Clin Immunol (1998) 1.52
Immune mechanisms of allergen-specific sublingual immunotherapy. Allergy (2006) 1.40
Immunoglobulin E antibody reactivity to the major shrimp allergen, tropomyosin, in unexposed Orthodox Jews. Clin Exp Allergy (2003) 1.23
Insect venom immunotherapy induces interleukin-10 production and a Th2-to-Th1 shift, and changes surface marker expression in venom-allergic subjects. Eur J Immunol (1997) 1.22
Induction of interleukin-10 and suppressor of cytokine signalling-3 gene expression following peptide immunotherapy. Clin Exp Allergy (2006) 1.19
Cockroach allergens and asthma in Brazil: identification of tropomyosin as a major allergen with potential cross-reactivity with mite and shrimp allergens. J Allergy Clin Immunol (1999) 1.18
Identification of tropomyosin as the major shrimp allergen and characterization of its IgE-binding epitopes. J Immunol (1993) 1.18
Effect of immunotherapy on immunoglobulin E and immunoglobulin G antibodies to ragweed antigens: a six-year prospective study. J Allergy Clin Immunol (1982) 1.13
Proteomics and immunological analysis of a novel shrimp allergen, Pen m 2. J Immunol (2003) 1.12
Identification of continuous, allergenic regions of the major shrimp allergen Pen a 1 (tropomyosin). Int Arch Allergy Immunol (2002) 1.07
IgE reactivity against a cross-reactive allergen in crustacea and mollusca: evidence for tropomyosin as the common allergen. J Allergy Clin Immunol (1996) 1.02
Immunomodulation of allergic disease. Annu Rev Med (2009) 1.02
Allergen-related approaches to immunotherapy. Pharmacol Ther (2008) 1.02
Clinical efficacy of sublingual and subcutaneous birch pollen allergen-specific immunotherapy: a randomized, placebo-controlled, double-blind, double-dummy study. Allergy (2004) 1.00
Analysis of the antibody responses induced by subcutaneous injection immunotherapy with birch and Fagales pollen extracts adsorbed onto aluminum hydroxide. Int Arch Allergy Immunol (2009) 0.90
Sarcoplasmic calcium-binding protein is an EF-hand-type protein identified as a new shrimp allergen. J Allergy Clin Immunol (2009) 0.90
Identification and molecular characterization of Charybdis feriatus tropomyosin, the major crab allergen. J Allergy Clin Immunol (1998) 0.89
Randomized controlled trial of high-dose sublingual immunotherapy to treat seasonal allergic rhinitis. J Allergy Clin Immunol (2004) 0.87
Clinical outcome and IL-17, IL-23, IL-27 and FOXP3 expression in peripheral blood mononuclear cells of pollen-allergic children during sublingual immunotherapy. Pediatr Allergy Immunol (2009) 0.85
The VISYT trial: Venom Immunotherapy Safety and Tolerability with purified vs nonpurified extracts. Ann Allergy Asthma Immunol (2009) 0.83
Identification of a shrimp-derived allergen as tRNA. J Immunol (1987) 0.81
Analysis of helper T cell responses to Cry j 1-derived peptides in patients with nasal allergy: candidate for peptide-based immunotherapy of Japanese cedar pollinosis. Allergol Int (2008) 0.77
Treatment of patients with the hypereosinophilic syndrome with mepolizumab. N Engl J Med (2008) 5.94
Catapult-like release of mitochondrial DNA by eosinophils contributes to antibacterial defense. Nat Med (2008) 4.93
Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy. J Allergy Clin Immunol (2009) 3.74
Approaches to the treatment of hypereosinophilic syndromes: a workshop summary report. J Allergy Clin Immunol (2006) 3.04
Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes. J Allergy Clin Immunol (2012) 2.78
Refining the definition of hypereosinophilic syndrome. J Allergy Clin Immunol (2010) 2.74
Immunologic response to fungus is not universally associated with rhinosinusitis. Otolaryngol Head Neck Surg (2009) 2.00
Chronic rhinosinusitis: an enhanced immune response to ubiquitous airborne fungi. J Allergy Clin Immunol (2004) 1.52
Endoplasmic reticulum aminopeptidase associated with antigen processing defines the composition and structure of MHC class I peptide repertoire in normal and virus-infected cells. J Immunol (2010) 1.46
Mice completely lacking immunoproteasomes show major changes in antigen presentation. Nat Immunol (2011) 1.45
Prognostic factors and risk stratification in early mycosis fungoides. Leuk Lymphoma (2013) 1.42
Prior human leukocyte antigen-allosensitization and left ventricular assist device type affect degree of post-implantation human leukocyte antigen-allosensitization. J Heart Lung Transplant (2009) 1.37
EGO, a novel, noncoding RNA gene, regulates eosinophil granule protein transcript expression. Blood (2007) 1.33
What targeting eosinophils has taught us about their role in diseases. J Allergy Clin Immunol (2010) 1.33
Striking deposition of toxic eosinophil major basic protein in mucus: implications for chronic rhinosinusitis. J Allergy Clin Immunol (2005) 1.27
Mepolizumab as a corticosteroid-sparing agent in lymphocytic variant hypereosinophilic syndrome. J Allergy Clin Immunol (2010) 1.25
A community-based tuberculosis program in Cambodia. JAMA (2004) 1.21
Elemental diet induces histologic response in adult eosinophilic esophagitis. Am J Gastroenterol (2013) 1.20
Eosinophil-derived cationic proteins activate the synthesis of remodeling factors by airway epithelial cells. J Immunol (2006) 1.17
Pathogenesis and classification of eosinophil disorders: a review of recent developments in the field. Expert Rev Hematol (2012) 1.15
A robust method for production of MHC tetramers with small molecule fluorophores. J Immunol Methods (2006) 1.15
A potent vaccination strategy that circumvents lymphodepletion for effective antitumor adoptive T-cell therapy. Cancer Res (2012) 1.14
Workshop report from the National Institutes of Health Taskforce on the Research Needs of Eosinophil-Associated Diseases (TREAD). J Allergy Clin Immunol (2012) 1.12
Direct expansion of human allospecific FoxP3+CD4+ regulatory T cells with allogeneic B cells for therapeutic application. J Immunol (2009) 1.11
Exploring potential noninvasive biomarkers in eosinophilic esophagitis in children. J Pediatr Gastroenterol Nutr (2011) 1.09
Patchy eosinophil distributions in an esophagectomy specimen from a patient with eosinophilic esophagitis: Implications for endoscopic biopsy. J Allergy Clin Immunol (2012) 1.09
Sequence variation in the gene encoding the nonstructural 3 protein of hepatitis C virus: evidence for immune selection. J Mol Evol (2002) 1.08
Hypereosinophilic syndrome: case presentation and update. J Allergy Clin Immunol (2004) 1.07
The induction of eosinophil peroxidase release: improved methods of measurement and stimulation. J Immunol Methods (2004) 1.07
Patient-derived models of human breast cancer: protocols for in vitro and in vivo applications in tumor biology and translational medicine. Curr Protoc Pharmacol (2013) 1.04
Modulation of the peripheral T-Cell response by CD4 mutants of hepatitis C virus: transition from a Th1 to a Th2 response. Hum Immunol (2003) 1.03
Novel targeted therapies for eosinophilic disorders. J Allergy Clin Immunol (2012) 1.02
Blood eosinophil count is a useful biomarker to identify patients with severe eosinophilic asthma. Ann Am Thorac Soc (2014) 1.00
Effects of eosinophils on mast cells: a new pathway for the perpetuation of allergic inflammation. Mol Immunol (2002) 0.99
Regulation of HLA-DR peptide occupancy by histone deacetylase inhibitors. Hum Vaccin Immunother (2013) 0.98
Large scale mass spectrometric profiling of peptides eluted from HLA molecules reveals N-terminal-extended peptide motifs. J Immunol (2008) 0.96
Plasma membrane calcium pumps in mouse olfactory sensory neurons. Chem Senses (2006) 0.96
Dermatologic manifestations of the hypereosinophilic syndromes. Immunol Allergy Clin North Am (2007) 0.96
Human eosinophils produce neurotrophins and secrete nerve growth factor on immunologic stimuli. Blood (2002) 0.96
Eosinophil major basic protein stimulates neutrophil superoxide production by a class IA phosphoinositide 3-kinase and protein kinase C-zeta-dependent pathway. J Immunol (2003) 0.95
Major basic protein homolog (MBP2): a specific human eosinophil marker. J Immunol (2006) 0.95
The spleen is a major site of megakaryopoiesis following transplantation of murine hematopoietic stem cells. Blood (2002) 0.95
The changing role of eosinophils in long-term hyperreactivity following a single ozone exposure. Am J Physiol Lung Cell Mol Physiol (2005) 0.94
Long-term safety of mepolizumab for the treatment of hypereosinophilic syndromes. J Allergy Clin Immunol (2012) 0.94
Utility of virtual crossmatch in sensitized patients awaiting heart transplantation. J Heart Lung Transplant (2009) 0.93
High quality and quantity Genome-wide germline genotypes from FFPE normal tissue. BMC Res Notes (2011) 0.91
In vitro responses to avian influenza H5 by human CD4 T cells. J Immunol (2009) 0.91
ERAAP and tapasin independently edit the amino and carboxyl termini of MHC class I peptides. J Immunol (2013) 0.90
Regulation of eosinophil membrane depolarization during NADPH oxidase activation. J Cell Sci (2003) 0.90
Mechanisms of eosinophil major basic protein-induced hyperexcitability of vagal pulmonary chemosensitive neurons. Am J Physiol Lung Cell Mol Physiol (2009) 0.89
Eosinophil major basic protein: first identified natural heparanase-inhibiting protein. J Allergy Clin Immunol (2004) 0.89
ICON: Eosinophil Disorders. World Allergy Organ J (2012) 0.88
Sensitization of isolated rat vagal pulmonary sensory neurons by eosinophil-derived cationic proteins. Am J Physiol Lung Cell Mol Physiol (2008) 0.88
The impact of bridge-to-transplant ventricular assist device support on survival after cardiac transplantation. J Thorac Cardiovasc Surg (2010) 0.88
Eosinophil granule protein localization in eosinophilic endomyocardial disease. N Engl J Med (2011) 0.88
Functionally distinct helper T-cell epitopes of HCV and their role in modulation of NS3-specific, CD8+/tetramer positive CTL. Hum Immunol (2002) 0.87
Biological activities of ecalectin: a novel eosinophil-activating factor. J Immunol (2002) 0.87
Utility of characteristic QTOF MS/MS fragmentation for MHC class I peptides. J Proteome Res (2011) 0.87
Human T cell expansion and experimental autoimmune encephalomyelitis inhibited by Lenaldekar, a small molecule discovered in a zebrafish screen. J Neuroimmunol (2012) 0.86
Increased FasL expression correlates with apoptotic changes in granulocytes cultured with oxidized clozapine. Toxicol Appl Pharmacol (2006) 0.86
Eosinophil-granule major basic protein, a C-type lectin, binds heparin. Biochemistry (2005) 0.85
Identification and validation of shrimp-tropomyosin specific CD4 T cell epitopes. Hum Immunol (2013) 0.84
Antigen-specific IgG and IgA, but not IgE, activate the effector functions of eosinophils in the presence of antigen. Int Arch Allergy Immunol (2010) 0.84
Hepatitis C virus induces regulatory T cells by naturally occurring viral variants to suppress T cell responses. Clin Dev Immunol (2010) 0.84
Donor-reactive HLA antibodies in renal allograft recipients: considerations, complications, and conundrums. Hum Immunol (2009) 0.84
Differential extraction of eosinophil granule proteins. J Immunol Methods (2005) 0.84
Activated eosinophils in association with enteric nerves in inflammatory bowel disease. PLoS One (2013) 0.84
The effect of cationic charge on release of eosinophil mediators. J Allergy Clin Immunol (2008) 0.84
Identification of basophils by a mAb directed against pro-major basic protein 1. J Allergy Clin Immunol (2006) 0.84
Higher SLPI expression, lower immune activation, and increased frequency of immune cells in a cohort of Colombian HIV-1 controllers. J Acquir Immune Defic Syndr (2012) 0.83
Atropine-enhanced, antigen challenge-induced airway hyperreactivity in guinea pigs is mediated by eosinophils and nerve growth factor. Am J Physiol Lung Cell Mol Physiol (2009) 0.83
Effect of eosinophil adhesion on intracellular signaling in cholinergic nerve cells. Am J Respir Cell Mol Biol (2003) 0.82
Natural epitope variants of the hepatitis C virus impair cytotoxic T lymphocyte activity. World J Gastroenterol (2010) 0.82
Eosinophil ribonucleases and their cutaneous lesion-forming activity. J Immunol (2009) 0.82
Validation of cytomegalovirus immune competence assays for the characterization of CD8(+) T cell responses posttransplant. Clin Dev Immunol (2012) 0.81
Interactions between helper T-cell epitopes of hepatitis C virus. Vaccine (2005) 0.81
Treatment of asthma with nebulized lidocaine: a randomized, placebo-controlled study. J Allergy Clin Immunol (2004) 0.81
Interactions of eosinophil granule proteins with skin: limits of detection, persistence, and vasopermeabilization. J Allergy Clin Immunol (2003) 0.81
Effects of eosinophils on nerve cell morphology and development: the role of reactive oxygen species and p38 MAP kinase. Am J Physiol Lung Cell Mol Physiol (2003) 0.81
Evidence for pathogenic involvementof eosinophils and neutrophilsin Churg-Strauss syndrome. J Am Acad Dermatol (2002) 0.80
Naturally occurring CD4+ T-cell epitope variants act as altered peptide ligands leading to impaired helper T-cell responses in hepatitis C virus infection. Hum Immunol (2011) 0.80
Cryptic infection and autoimmunity. Autoimmun Rev (2003) 0.80
Specificity of EIA immunoassay for complement factor Bb testing. Clin Lab (2011) 0.80
Eosinophil recruitment to nasal nerves after allergen challenge in allergic rhinitis. Clin Immunol (2013) 0.80
⁹⁹mTechnetium-labeled heparin: a new approach to detection of eosinophilic esophagitis-associated inflammation. J Allergy Clin Immunol (2013) 0.79
Binding of anti-HLA class I antibody to endothelial cells produce an inflammatory cytokine secretory pattern. J Clin Lab Anal (2009) 0.79
Development and validation of a fluorescent microsphere immunoassay for soluble CD30 testing. Clin Vaccine Immunol (2009) 0.79